Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)

Telix Pharmaceuticals has reported Current Leases over the past 3 years, most recently at $5.5 million for Q4 2025.

  • Quarterly Current Leases rose 239.89% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2025, up 239.89% year-over-year, with the annual reading at $5.5 million for FY2025, 258.86% up from the prior year.
  • Current Leases was $5.5 million for Q4 2025 at Telix Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over five years, Current Leases peaked at $5.5 million in Q4 2025 and troughed at $387339.3 in Q4 2023.
  • The 3-year median for Current Leases is $1.6 million (2024), against an average of $2.5 million.
  • Year-over-year, Current Leases skyrocketed 321.41% in 2024 and then skyrocketed 239.89% in 2025.
  • A 3-year view of Current Leases shows it stood at $387339.3 in 2023, then skyrocketed by 321.41% to $1.6 million in 2024, then skyrocketed by 239.89% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Current Leases are $5.5 million (Q4 2025), $1.6 million (Q4 2024), and $387339.3 (Q4 2023).